


## Attachment A-2

DIVISIONAL APPLICATION 2

## CLAIMS


1. A heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof:



10       **wherein:**

R<sup>1</sup> is aryl; said aryl being optionally substituted by the same or different one to three groups selected from alkyl, haloalkyl, trihaloalkyl, alkoxy, halogen and nitro;

**E is a group of the formula [3]:**



[ 3 ]

15            wherein Y is oxygen or sulfur; R<sup>3</sup> is hydrogen or alkyl; p is an integer of 0-2; Z is carboxy, alkoxycarbonyl, hydroxymethyl, carbamoyl, N-hydroxycarbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, cyano, 1H-5-tetrazolyl, 1-alkyl-5-tetrazolyl, or 2-alkyl-5-tetrazolyl;

20           Het and D correspond to any one of the following cases  
(1) to (2)

(1)

Het is a thiazole which is optionally substituted by alkyl or trihaloalkyl;


D is alkylene, alkenylene, or alkynylene; and

5

(2)

Het is an oxazole which is optionally substituted by alkyl or trihaloalkyl; and

D is a group of the formula [2]:



[ 2 ]

10 wherein m is an integer of 1 - 10 and n is an integer of 0 - 9, with the proviso that m + n is an integer of 1 - 10.

2. A therapeutic pharmaceutical composition for hyperlipidemia, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a  
15 pharmaceutically acceptable salt thereof:

3. A therapeutic pharmaceutical composition for arteriosclerosis, comprising as an active ingredient a heterocyclic compound as set forth in claims 1, or a  
20 pharmaceutically acceptable salt thereof.

4. A therapeutic pharmaceutical composition for ischemic heart disease, comprising as an active ingredient a heterocyclic compound as set forth claim 1, or a  
25 pharmaceutically acceptable salt thereof.

5. A therapeutic pharmaceutical composition for cerebral infarction, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

5

6. A therapeutic pharmaceutical composition for reocclusion after PTCA, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

10

7. A therapeutic pharmaceutical composition for diabetes mellitus, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

15

8. A therapeutic pharmaceutical composition for obesity, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.